에 대한 최신 뉴스 Intuitive Surgical (NASDAQ:ISRG) 주식

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.

Analyst Color

Long Ideas

Sector ETFs

Analyst Ratings

Tech

Trading Ideas

ETFs

ABBNY

ISRG

NVDA

PATH

PLTR

ZBRA

미국의 경쟁력은 2025년에 네 가지 주요 투자 테마인 에너지 독립, 방산 혁신, 인프라 및 자동화가 포트폴리오 성장을 강화할 태세를 갖추면서 중심 무대로 떠오른다. 스콧 헬프스타인(Scott Helfstein)이 이끄는 글로벌 X의 2025년 투자 전망은 이러한 변혁적인 트렌드를 향후 1년 동안의 회복력의 중요한 동력으로 강조하고 있다.

2025 투자 테마: 인공지능, 에너지 및 방산이 미국 시장을 재정의

Exclusives

INSM

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

News

Markets

General

AAPL

AVGO

BOTZ

CSCO

FTEC

iShares Dow Jones US Technology Sector Index Fund

MSFT

ORCL

인공지능(AI)을 테마로 한 상장지수펀드(ETF)는 자산 운용사들이 인공지능을 둘러싼 관심이 높아지는 것을 활용하면서 상당한 급증을 목격하고 있다. 모닝스타(Morningstar)에 따르면 올해 AI 중심 ETF 24개 중 1/3 이상이 출시되었다.

2024년에 AI 기반 ETF의 1/3 이상이 출시: 엔비디아, MS, 애플 및 메타 등을 중점

Intuitive Surgical Inc

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 5 years by 8.96% on an annualized basis producing an average annual return of 22.57%. Currently, Intuitive Surgical has a market capitalization of $194.20 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 5 years ago, it would be worth $277.84 today based on a price of $545.23 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734364809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Intuitive Surgical 5 Years Ago Would Be Worth This Much Today

Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $567 to $640.

Price Target

Citigroup Maintains Buy on Intuitive Surgical, Raises Price Target to $640

U.S. competitiveness takes center stage in 2025 with four key investment themes—energy independence, defense innovation, infrastructure, and automation—poised to bolster portfolio growth. Global X's 2025 Investment Outlook, led by Scott Helfstein, highlights these transformative trends as critical drivers of resilience <a href="https://www.benzinga.com/topic/us-economy">in the coming year.</a>
<h2 class="wp-block-heading">Infrastructure Gets A Glow-Up</h2>
America&#8217;s infrastructure renaissance is going full throttle, with $700 billion in spending set to energize construction, equipment, and materials companies. This may bode well for investors in the Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>).
These stalwarts of the old economy are reinventing themselves with cutting-edge tech to expand margins—all while trading at attractive valuations compared to the broader S&amp;P 500.
<h2 class="wp-block-heading">The Defense Play: Beyond Jets &amp; Ships</h2>
Global tensions are driving a pivot from traditional defense platforms to high-tech solutions like AI-driven drones and cybersecurity systems. 
Palantir Technologies Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) Artificial Intelligence Platform and International Business Machines Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) WatsonX AI come to mind here.
Defense revenues are expected to jump nearly 10%, with margins climbing from 5.2% to 7.6%. Success will favor those adopting automation and next-generation technologies in this competitive landscape.
Read Also: <a href="https://www.benzinga.com/news/small-cap/24/12/42438879/manufacturing-tariffs-small-cap-could-steal-the-show-in-2025">Manufacturing Comeback? Strategist Expects Tariffs To Help Small-Cap Stocks But Weigh On Consumers</a>
<h2 class="wp-block-heading">Automation &amp; Onshoring: A Tech Revolution</h2>
With the U.S. accelerating its onshoring efforts, automation and AI are emerging as the driving forces powering the shift.
Software companies and data centers are prepping for a revenue surge, with mega-cap tech upping its spending on data centers to $250 billion in 2025. 
Robotics and IoT hardware could also rebound from a sales plateau, making the automation sector one to watch. Companies enabling robotics and automation such as Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), ABB (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>), Rockwell Automation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), Zebra Technologies&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>), Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) and UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) come to mind.
<h2 class="wp-block-heading">Energy Independence Goes Nuclear</h2>
Energy's next frontier? Nuclear. With mega-cap tech giants eyeing modular nuclear reactors as a green and reliable power source, demand for uranium is heating up. Beyond the U.S., countries like Japan and Germany are also jumping on the nuclear bandwagon, signaling a global shift toward energy resilience.
U.S. companies such as Constellation Energy&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), Cameco&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) and NuScale Power&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) come to mind.
Helfstein's roadmap suggests a year of targeted strategies. By aligning portfolios with these U.S.-centric themes, investors might not just weather volatility—they could thrive in the chaos.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/24/12/42437267/berkshire-palantir-etfs-add-high-octane-trading-options-with-direxions-launch">Berkshire, Palantir ETFs Add High-Octane Trading Options With Direxion&#8217;s Launch</a></li>
</ul>
Photo: Shutterstock

2025 Investment Themes: AI, Energy, Defense Redefine US Markets

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) from $96 to $100. Keybanc analyst Bradley Thomas maintained an Overweight rating. Walmart shares closed at $94.55 on Tuesday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted the price target for Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) from $31 to $34. Truist Securities analyst Jailendra Singh maintained a Buy rating. Phreesia shares closed at $24.14 on Tuesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) price target from $56 to $42. Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight. RxSight shares settled at $39.17 on Tuesday. <a href="https://www.benzinga.com/quote/RXST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Trimble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NYSE">TRMB</a>) price target from $77 to $88. Oppenheimer analyst Kristen Owen maintained an Outperform rating. Trimble shares closed at $74.12 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) price target from $40 to $35. Morgan Stanley analyst Vikram Purohit maintained an Overweight rating. Zenas BioPharma shares closed at $9.50 on Tuesday.  <a href="https://www.benzinga.com/quote/ZBIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna boosted Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $339 to $375. Susquehanna analyst James Friedman maintained a Positive rating on the stock. Visa shares closed at $312.38 on Tuesday. See how other analysts view this stock.</li>
<li>Piper Sandler raised the price target for Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) from $56 to $64. Piper Sandler analyst Brad Milsaps maintained an Overweight rating. Synovus Financial shares settled at $55.14 on Tuesday. <a href="https://www.benzinga.com/quote/SNV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) price target from $88 to $130. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. United Airlines shares closed at $96.53 on Tuesday. <a href="https://www.benzinga.com/quote/UAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from $549 to $630. Wells Fargo analyst Larry Biegelsen maintained an Overweight rating. Intuitive Surgical shares closed at $538.09 on Tuesday. <a href="https://www.benzinga.com/quote/ISRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Columbia Sportswear Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) price target from $92 to $100. Stifel analyst Jim Duffy maintained a Buy rating. Columbia Sportswear shares closed at $90.09 on Tuesday. <a href="https://www.benzinga.com/quote/COLM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42432935/top-3-health-care-stocks-that-may-collapse-this-quarter">Top 3 Health Care Stocks That May Collapse This Quarter</a></li>
</ul>

COLM

RXST

TRMB

ZBIO

Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $549 to $630.

Wells Fargo Maintains Overweight on Intuitive Surgical, Raises Price Target to $630

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 20.53%. Currently, Intuitive Surgical has a market capitalization of $191.66 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 15 years ago, it would be worth $16,578.15 today based on a price of $538.09 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733866213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Intuitive Surgical 15 Years Ago Would Be Worth This Much Today

Analysis included 230 studies—a mix of randomized, prospective, and database research
SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)
The peer-reviewed Annals of Surgery published <a href="https://www.globenewswire.com/Tracker?data=t_P3T_mDtq2kQ-Bi4_0x2CyvRROUzqRDr5pa0PuiyACM_QTjkCRQyPyAEmlDKODYWFaurEgI1IvSIuk_ZloeRopi6fr9lJwCP7rdbJ8vm50w1rzTyn8tQPVo9xwuDQyO1yA-xt7_gTqNpOitnCL6DWV_2TNfu8_y46YafHmT_sadf_imPZxoZm01Z4F2PqE0UTzwEOy3k0T34XXPgmE5RV7V2BJAPxch1JpAXkdpR2Hhznp4drDsZwdnGbb9-MAg94YzvWJWYI1rsdsMDa61XOlKF90Fbdfi-xsRjZAk7ug=">a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures</a>, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective studies, and 122 database reviews. Each surgical approach represented more than a million procedures.
The meta-analysis, conducted by scientists from Intuitive and Massachusetts General Hospital, demonstrated multiple benefits for robotic surgery using Intuitive's da Vinci system as compared to laparoscopy and open surgery.

Biotech

Intuitive Surgical Announces The Peer-Reviewed Annals Of Surgery Published A Meta-Analysis Of 30-Day Surgical Outcomes Across Seven Oncological Surgical Procedures, Comparing Robotic, Laparoscopic, And Open Surgical Approaches

Intuitive Surgical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 7.34% since its last report. The company recently reported that it has 4.15 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733418014_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 4.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(ISRG) - Analyzing Intuitive Surgical's Short Interest

Stifel analyst Rick Wise maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $525 to $610.

Stifel Maintains Buy on Intuitive Surgical, Raises Price Target to $610

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Upgrades

Downgrades

Health Care

Movers

DXCM

EMBC

GKOS

GMED

IRTC

NVRO

PRCT

STAA

TMDX

TNDM

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Morgan Stanley analyst Cecilia Furlong upgrades Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from Equal-Weight to Overweight and raises the price target from $522 to $650.

Morgan Stanley Upgrades Intuitive Surgical to Overweight, Raises Price Target to $650

Whales with a lot of money to spend have taken a noticeably bullish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 9% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $77,900 and 9, calls, for a total amount of $448,950.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $560.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 157.75 with a total volume of 182.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $240.0 to $560.0 over the last 30 days.
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644997_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$19.6</td>
<td>$19.7</td>
<td>$550.00</td>
<td>$78.8K</td>
<td align="right">575</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$65.0</td>
<td>$60.7</td>
<td>$65.0</td>
<td>$520.00</td>
<td>$65.0K</td>
<td align="right">173</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$64.9</td>
<td>$61.4</td>
<td>$63.0</td>
<td>$520.00</td>
<td>$63.0K</td>
<td align="right">173</td>
<td align="right">20</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$305.0</td>
<td>$300.7</td>
<td>$302.7</td>
<td>$240.00</td>
<td>$60.5K</td>
<td align="right">52</td>
<td align="right">2</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.8</td>
<td>$27.6</td>
<td>$28.8</td>
<td>$560.00</td>
<td>$57.6K</td>
<td align="right">140</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a trading volume of 478,667, the price of ISRG is up by 0.66%, reaching $540.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in Intuitive Surgical

BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $535 to $561.

BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $561

Erste Group analyst Hans Engel upgrades Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) from Hold to Buy.

Erste Group Upgrades Intuitive Surgical to Buy

Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is a &#8220;fantastic company with an expensive stock,&#8221; <a href="https://www.benzinga.com/topic/jim-cramer">according to CNBC's Jim Cramer</a>.
On Oct. 17, Intuitive Surgical reported third-quarter revenue of $2.04 billion, beating the consensus estimate of $2 billion.
During the latest edition of &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Cramer said Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) <a href="https://www.benzinga.com/quote/ET/earnings">is a buy</a>.
Energy Transfer reported quarterly earnings of 32 cents per share which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $20.772 billion which missed the analyst consensus estimate of $22.297 billion.
&#8220;Let it ride,&#8221; Cramer said when asked about T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>).
On Oct. 23, T-Mobile reported quarterly earnings of $2.61 per share, which beat the analyst consensus estimate of $2.41 per share.
Cramer recommended buying Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>). &#8220;I think it still works higher,&#8221; he added.
On Nov. 4, Constellation Energy reported third-quarter results and revised its FY24 adjusted EPS guidance, which is below estimates.
When asked about International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), he said, &#8220;I think we can hold it.&#8221;
On Oct. 23, IBM reported third-quarter revenue of $14.968 billion, missing the consensus estimate of $15.07 billion, according to Benzinga Pro.
The Mad Money host said he is not recommending Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). &#8220;I think they have a lot of companies that are up against them,&#8221; he noted.
On Nov. 11, Keybanc analyst Eric Heath maintained Snowflake with an Overweight and lowered the price target from $168 to $150.
Price Action:
<ul>
<li>Energy Transfer shares fell 1.1% to settle at $17.05 on Tuesday.</li>
<li>Intuitive Surgical shares gained 0.3% to close at $537.07.</li>
<li>T-Mobile shares rose 0.3% to close at $239.00 on Tuesday.</li>
<li>Constellation Energy shares fell 3.6% to settle at $228.70 during the session.</li>
<li>IBM shares fell 0.5% to close at $210.86 on Tuesday.</li>
<li>Snowflake shares gained 1.6% to settle at $125.46.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41899303/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-in-q4">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio In Q4</a></li>
</ul>
Courtesy of Intuitive Surgical

Media

SNOW

TMUS

Jim Cramer Says Intuitive Surgical Is A 'Fantastic, Expensive Company'

Intuitive Surgical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 9.0% since its last report. The company recently reported that it has 3.85 million shares sold short, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731430819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 4.16%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Intuitive Surgical?

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Nov. 8:
Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>): The biopharmaceutical company saw increased interest from investors over the week, which comes after the company <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update">reported </a>third-quarter financial results and provided a company update in late October. The company said ARIKAYCE had revenue of $93.4 million in the quarter, up 18% year-over-year. 
Insmed also said its NDA submission for Brensocatib in Bronchiectasis is on track for the fourth quarter and is expected to launch in the U.S. in mid-2025. 
H.C. Wainwright reiterated a Buy rating and $90 price target on the stock <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">after the quarterly results</a>. Truist reiterated a Buy rating and raised the price target from $100 to $105. Investor interest could increase in the coming weeks with the company scheduled to participate in several conferences including ones from Guggenheim (Nov. 11), UBS Global (Nov. 12), Wolfe Research (Nov. 20) and Jefferies (Nov. 21).
Insmed shares were up over 8% in the last five trading days, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 140% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png" alt="" class="wp-image-638350" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-768x389.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Applied Industrial Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>): The industrial company was one of several in the sector to see strong interest from readers, which could be related to Donald Trump winning<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> the 2024 election.</a> Industrials were a top performing sector under <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">Trump&#8217;s previous four years</a> in the White House. 
The company also recently <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx">reported </a>first-quarter financial results with earnings per share of $2.36 and revenue of $1.10 billion, beating Street consensus estimates of $2.27 and $1.09 billion respectively. Applied Industrial also increased its fiscal 2025 earnings per share guidance to a range of $9.25 to $10.00, up from prior guidance of $9.20 to $9.95 and ahead of a Street estimate of $9.39. 
Analysts <a href="https://www.benzinga.com/quote/AIT/analyst-ratings">raised their price targets</a> on the stock after the quarterly results. The stock was up over 15% in the last five trading days and is up over 50% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png" alt="" class="wp-image-638351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>): The specialty grocery retailer saw strong interest from Benzinga readers during the week, which comes after <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx">recent </a>quarterly results and with shares trading at 52-week highs. The company's third-quarter earnings per share of 91 cents and revenue of $1.90 billion beat Street estimates of 76 cents per share and $1.88 billion respectively.
The company said the third quarter was exceptional and CEO Jack Sinclair highlighted "robust traffic growth." Same store sales were up 8.4% in the third quarter. The company opened nine new stores, ending the quarter with 428 stores in 23 states. 
Goldman Sachs recently <a href="https://www.benzinga.com/quote/SFM/analyst-ratings">maintained a Buy rating </a>on the stock and raised the price target from $127 to $159. Wells Fargo maintained an Equal-Weight rating on the stock and raised the price target from $90 to $130. 
The stock was up over 10% over the last five trading days, and shares are up over 190% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png" alt="" class="wp-image-638353" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): The medical devices company saw strong interest from readers over the last week, with shares trading at 52-week highs Friday. 
The company recently reported <a href="https://www.benzinga.com/news/earnings/24/10/41391471/intuitive-surgical-stock-pops-on-q3-earnings-beat-da-vinci-procedures-climb-18-regulatory-clearance">third-quarter financial results </a>with revenue of $2.04 billion beating a Street consensus estimate of $2.0 billion and earnings per share of $1.84 beating a Street consensus estimate of $1.63. Intuitive Surgical reported revenue growth of 17% year-over-year in the quarter, with worldwide da Vinci procedures up 18% year-over-year. 
The company also placed 379 da Vinci systems in the quarter, up from 312 in the prior quarter. There are 9,539 installed da Vinci surgical systems as of the end of the quarter. Intuitive obtained regulatory clearance for the da Vinci 5 surgical system in South Korea in October. 
The earnings report saw several<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt"> analysts raise their price targets </a>on the stock. Analysts see the company's updated da Vinci 5 system, which can be used for more types of surgeries as a growth catalyst moving forward. Shares of Intuitive Surgical were up around six percent in the last five days and are up over 60% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png" alt="" class="wp-image-638354" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>): The industrials company was another in the sector that saw increased interest and a soaring stock price, potential from Trump's 2024 election win. The company recently <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings">reported </a>third-quarter net sales of $997.8 million, beating a Street consensus estimate of $936.0 million and quarterly earnings per share of $1.48, which beat a Street estimate of $1.32. Mueller Industries said the revenue growth came from recently acquired businesses and higher copper prices in the quarter.
"We anticipated that declining interest rates and moderating inflation, combined with the resolution of election related uncertainty, will create a more stable and favorable environment for us," Mueller CEO Greg Christopher said.
The stock was up 13% over the last five days and is up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png" alt="" class="wp-image-638355" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">November 1</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>
Photo: Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

On CNBC's &#8220;Mad Money Lightning Round,&#8221; <a href="https://www.benzinga.com/topic/jim-cramer">Jim Cramer recommended</a> buying Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).
On Oct. 17, Intuitive Surgical reported third-quarter revenue of $2.04 billion, beating the consensus estimate of $2 billion. The robotic-assisted surgery company reported third-quarter adjusted earnings of $1.84 per share, beating analyst estimates of $1.63 per share, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Kimco Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) is a &#8220;great operator, just own it right through,&#8221; he said.
On Oct. 1, Kimco Realty announced the acquisition of Waterford Lakes Town Center, a 976,000-square-foot signature asset spanning 79 acres in Orlando, Florida, for $322 million, including the assumption of a $164 million mortgage.
&#8220;That is such a hard story to understand,&#8221; Cramer said when asked about Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>).
On Oct. 28, Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $71 to $72.
The &#8220;Mad Money&#8221; host said CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is a buy.
On Oct. 22, CrowdStrike partnered with Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) to enhance endpoint and firewall protection by integrating its AI-native security from the Falcon platform with FortiGate next-generation firewalls (NGFW).
Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) is a &#8220;high speculative&#8221; stock, he said.
On Oct. 24, Keybanc analyst Michael Leshock maintained Rocket Lab with an Overweight and raised the price target from $11 to $12.
Price Action:
<ul>
<li>Intuitive Surgical shares gained 1.1% to settle at $516.31 on Tuesday.</li>
<li>Kimco shares declined 0.9% to close at $23.67 on Tuesday.</li>
<li>Nutanix shares rose 1.3% to settle at $64.97 during the session.</li>
<li>CrowdStrike shares gained 3.2% to settle at $310.94 on Tuesday.</li>
<li>Rocket Lab gained 1.9% to settle at $11.47 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>
Photo: s_bukley/Shutterstock.com

CRWD

FTNT

NTNX

RKLB

Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A 'High Speculative' Stock

AI-themed exchange-traded funds (ETFs) are witnessing a significant surge as asset managers capitalize on the growing enthusiasm surrounding <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence</a>. This year, over one-third of the two dozen AI-focused ETFs were launched, according to Morningstar.
What Happened: In the past week alone, three new ETFs have entered the AI sector, including one that was rebranded to specifically focus on artificial intelligence, Reuters reported on Monday. The total assets of AI ETFs have now reached $4.5 billion, approaching the $5.5 billion held by nuclear power-themed ETFs and surpassing the $1.37 billion in the cannabis sector.
Daniel Sotiroff, a senior analyst at Morningstar, remarked on the trend, stating, &#8220;I&#8217;m not surprised their ranks are multiplying.&#8221; 
He emphasized that the industry&#8217;s rapid pace attracts investors eager for quick returns, according to the report.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41560703/november-interest-rate-cut-almost-a-done-deal-as-blackout-begins-10-stocks-surging-the-most-sinc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">November Interest Rate Cut Almost A Done Deal As Blackout Begins: 10 Stocks Surging The Most Since Fed&#8217;s Last Decision</a>
As per Benzinga Pro data, here are how some of the AI-based ETFs performed over the past year:
Global X Robotics and Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>): BOTZ, currently with net assets worth $2.51 billion and NAV of $31.59, climbed 40.39%. Its top AI-related holdings include Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and biotech firm Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).
Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>): AIQ, which has $2.27 billion in net assets and $37.36 NAV, increased by 43.64%. Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), and Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) are some of its top AI-related holdings.
iShares US Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>): IYW gained 50.72% in the past year. The ETF has an NAV of $155.42 and $19.24 billion in net assets. It also gives exposure to tech stocks like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia, Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) which have witnessed stellar growth, thanks to AI buzz.
Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>): The ETF witnessed a 48.55% growth while exposing to stocks like Apple, Microsoft, Nvidia, Alphabet and Broadcom. It holds $12.05 billion in net assets. 
Why It Matters: The surge in AI-themed ETFs is part of a broader trend driven by the increasing demand for artificial intelligence technologies. Recently, Nvidia briefly surpassed Apple to become the <a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again">world&#8217;s most valuable company</a>, fueled by the demand for its AI supercomputing chips. This highlights the growing importance of AI in the tech sector.
Moreover, the <a href="https://www.benzinga.com/news/24/10/41351070/imf-warns-ai-in-stock-trading-can-boost-efficiency-but-warns-of-increased-market-volatility">International Monetary Fund</a> (IMF) has noted AI&#8217;s potential to enhance market efficiency but warns of increased volatility and cyber threats. The IMF&#8217;s Global Financial Stability Report suggests that AI-driven trading could revolutionize markets, although its adoption remains limited. The report also cautions about the potential shift of investments to less regulated nonbank financial intermediaries, complicating market oversight.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41517027/five-us-banks-face-billions-in-losses-as-silvers-price-spike-hits-short-sellers-hard-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Five US Banks Face Billions In Losses As Silver&#8217;s Price Spike Hits Short Sellers Hard: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

More Than A Third Of AI-Based ETFs Were Launched In 2024, Focusing On Nvidia, Microsoft, Apple And Meta, Among Others: Here's How Some Of Them Have Performed This Year So Far

Financial giants have made a conspicuous bearish move on Intuitive Surgical. Our analysis of options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) revealed 8 unusual trades.
Delving into the details, we found 12% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $426,801, and 6 were calls, valued at $285,918.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $350.0 to $520.0 for Intuitive Surgical over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 147.75 with a total volume of 588.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $350.0 to $520.0 over the last 30 days.
<h3>Intuitive Surgical 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729888259_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$7.9</td>
<td>$7.9</td>
<td>$465.00</td>
<td>$253.5K</td>
<td style="text-align: right;">94</td>
<td style="text-align: right;">322</td>
</tr>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$47.1</td>
<td>$46.7</td>
<td>$46.9</td>
<td>$500.00</td>
<td>$173.2K</td>
<td style="text-align: right;">57</td>
<td style="text-align: right;">42</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$168.7</td>
<td>$167.6</td>
<td>$168.6</td>
<td>$350.00</td>
<td>$67.4K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$37.3</td>
<td>$36.7</td>
<td>$37.0</td>
<td>$520.00</td>
<td>$55.5K</td>
<td style="text-align: right;">92</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$170.5</td>
<td>$168.6</td>
<td>$168.6</td>
<td>$350.00</td>
<td>$50.5K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">3</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a volume of 979,283, the price of ISRG is down -0.07% at $511.27. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 88 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $543.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Intuitive Surgical, maintaining a target price of $525. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $570. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Intuitive Surgical with a target price of $565. 
&#x2A; An analyst from Raymond James persists with their Outperform rating on Intuitive Surgical, maintaining a target price of $540. 
&#x2A; An analyst from BTIG has decided to maintain their Buy rating on Intuitive Surgical, which currently sits at a price target of $518. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuitive Surgical with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on ISRG Options

Morgan Stanley upgraded Intuitive Surgical (ISRG) to Overweight from Equal Weight with a price target of $650, up from $522, as the analyst assumed...

Intuitive Surgical assumed at Overweight from Equal Weight at Morgan Stanley

Morgan Stanley bullish on medtech in 2025, upgrades 5 stocks

Stifel raised the firm's price target on Intuitive Surgical (ISRG) to $610 from $525 and keeps a Buy rating on the shares. After having had in-dept...

Intuitive Surgical price target raised to $610 from $525 at Stifel

The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures, comparing r...

Intuitive announces publication of 30-day surgical outcomes involving da Vinci

Columbia Select Large Cap Growth Fund Q3 2024 Commentary

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2024 Update

In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Intuitive Surgical (ISRG – Research Report), with a price t...

Wells Fargo Sticks to Its Buy Rating for Intuitive Surgical (ISRG)

Citi raised the firm's price target on Intuitive Surgical (ISRG) to $640 from $567 and keeps a Buy rating on the shares as part of a 2025 outlook f...

Intuitive Surgical price target raised to $640 from $567 at Citi

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

Inspired by a previous post, here is a brief look at the top eight performing stocks over the past twenty years.

The Great Eight

ABBV

ACHC

ADBE

ADPT

AMAT

AMGN

AMZN

BBIO

BKNG

BLCO

BMRN

CBRE

CMCSA

COST

CTVA

DASH

DDOG

DLTR

EWTX

FERG

FLUT

GOOG

GOOGL

INBX

INTU

MDLZ

MNST

MSCI

NAMS

NFLX

ORIC

PEPG

PHVS

ROIV

RPRX

SBUX

SPOT

TEAM

TRVI

TSLA

TTWO

UBER

VKTX

WDAY

Untitled design - 2024-12-10T185819.364

Movers & Shakers

MBOT

Palm-Sized Innovation: How Microbot Medical Is Helping Redefine Surgical Robotics

Press Releases

Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy

Earnings

Intuitive Announces Second Quarter Earnings

Management

Intuitive President David J. Rosa Appointed to Intuitive Board of Directors

Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

Intuitive Announces Third Quarter Earnings

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029

Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open

Comments

Intuitive Surgical

뉴스

에 대한 최신 뉴스 Intuitive Surgical (NASDAQ:ISRG) 주식

목요일, 12월 12, 2024

토요일, 11월 09, 2024

월요일, 10월 28, 2024

목요일, 10월 17, 2024

목요일, 7월 25, 2024

금요일, 4월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌